Cite
HARVARD Citation
Peyvandi, F. et al. (2017). Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis. pp. 1448-1452. [Online].